Cumulative life course impairment: Evidence for psoriasis

Dermatological Diseases and Cumulative Life Course Impairment

Volumn 44, Issue , 2013, Pages 82-90

  Mattei, Peter L ^a   Corey, Kristen C ^b   Kimball, Alexa B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925862164     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000350008     Document Type: Chapter

References (91)

1. Vardy D, Besser A, Amir M, Gesthalter B, Biton A, Buskila D: Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 2002; 147: 736-742.
2. Ginsburg IH, Link BG: Psychosocial consequences of rejection and stigma feelings in psoriasis patients. Int J Dermatol 1993; 32: 587-591.
3. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ: Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47: 512-518.
4. Koo J: Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485-496.
5. Kleyn CE, McKie S, Ross AR, Montaldi D, Gregory LJ, Elliott R, et al: Diminished neural and cognitive responses to facial expressions of disgust in patients with psoriasis: a functional magnetic resonance imaging study. J Invest Dermatol 2009; 129: 2613-2619.
6. Schmid-Ott G, Kunsebeck HW, Jager B, Sittig U, Hofste N, Ott R, et al: Significance of the stigmatization experience of psoriasis patients: a 1-year followup of the illness and its psychosocial consequences in men and women. Acta Derm Venereol 2005; 85: 27-32.
7. Fox FE, Rumsey N, Morris M: 'Ur skin is the thing that everyone sees and you can't change it!': Exploring the appearance-related concerns of young people with psoriasis. Dev Neurorehabil 2007; 10: 133-141.
8. Eghlileb AM, Davies EE, Finlay AY: Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007; 156: 1245-1250.
9. Sampogna F, Gisondi P, Tabolli S, Abeni D, IDI Multipurpose Psoriasis Research on Vital Experiences Investigators: Impairment of sexual life in patients with psoriasis. Dermatology 2007; 214: 144-150.
10. McKenna KE, Stern RS: The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol 1997; 36: 388-394.
11. Frangos JE, Kimball AB: Divorce/marriage ratio in patients with psoriasis compared to patients with other chronic medical conditions. J Invest Dermatol 2008; 128(suppl 1):S87.
12. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M: Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-328.
13. Lynde CW, Poulin Y, Guenther L, Jackson C: The burden of psoriasis in Canada: Insights from the pSoriasis knowledge IN Canada (SKIN) survey. J Cutan Med Surg 2009; 13: 235-252.
14. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN:Suicidal ideation in psoriasis. Int J Dermatol 1993; 32: 188-190.
15. Higgins EM, Peters TJ, du Vivier AW: Smoking, drinking and psoriasis. Br J Dermatol 1993; 129: 749-750.
16. Waters HC, Carter CT, Piech CT, et al: The impact of psoriasis on psychological functioning and quality of life. JAAD 2009; 60(suppl 1):AB183.
17. Poikolainen K, Karvonen J, Pukkala E: Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999; 135: 1490-1493.
18. Kirby B, Richards HL, Mason DL, Fortune DG, Main CJ, Griffiths CE: Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol:2008; 158: 138-140.
19. Sampogna F, Picardi A, Chren MM, Melchi CF, Pasquini P, Masini C, et al: Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosom Med 2004; 66: 620-624.
20. Magin P, Adams J, Heading G, Pond D, Smith W:Experiences of appearance-related teasing and bullying in skin diseases and their psychological sequelae:Results of a qualitative study. Scand J Caring Sci 2008; 22: 430-436.
21. Forero R, McLellan L, Rissel C, Bauman A: Bullying behaviour and psychosocial health among school students in New South Wales, Australia: cross-sectional survey. BMJ 1999; 319: 344-348.
22. McCabe RE, Antony MM, Summerfeldt LJ, Liss A, Swinson RP: Preliminary examination of the relationship between anxiety disorders in adults and self-reported history of teasing or bullying experiences. Cogn Behav Ther 2003; 32: 187-193.
23. Gupta MA, Gupta AK: Psychiatric and psychological co-morbidity in patients with dermatologic disorders:epidemiology and management. Am J Clin Dermatol 2003; 4: 833-842.
24. Langley RG, Krueger GG, Griffiths CE: Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64(suppl 2):ii18, 23, discussion ii24-25.
25. Colman I, Wadsworth ME, Croudace TJ, Jones PB:Forty-year psychiatric outcomes following assessment for internalizing disorder in adolescence. Am J Psychiatry 2007; 164: 126-133.
26. Richards HL, Fortune DG, Griffiths CE, Main CJ:The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 2001; 50: 11-15.
27. Kleyn CE, Schneider L, Saraceno R, Mantovani C, Richards HL, Fortune DG, et al: The effects of acute social stress on epidermal Langerhans' cell frequency and expression of cutaneous neuropeptides. J Invest Dermatol 2008; 128: 1273-1279.
28. Miller AH, Maletic V, Raison CL: Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732-741.
29. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H: Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22: 370-379.
30. Sluzewska A, Sobieska M, Rybakowski JK: Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 1997; 35: 123-127.
31. Arck P, Paus R: From the brain-skin connection: the neuroendocrine-immune misalliance of stress and itch. Neuroimmunomodulation 2006; 13: 347-356.
32. Saraceno R, Kleyn CE, Terenghi G, Griffiths CE: The role of neuropeptides in psoriasis. Br J Dermatol 2006; 155: 876-882.
33. Schmid-Ott G, Jacobs R, Jager B, Klages S, Wolf J, Werfel T, et al: Stress-induced endocrine and immunological changes in psoriasis patients and healthy controls. A preliminary study. Psychother Psychosom 1998; 67: 37-42.
34. Schmid-Ott G, Jaeger B, Adamek C, Koch H, Lamprecht F, Kapp A, et al: Levels of circulating CD8(+) T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis. J Allergy Clin Immunol 2001; 107: 171-177.
35. Chaput JC, Poynard T, Naveau S, Penso D, Durrmeyer O, Suplisson D: Psoriasis, alcohol, and liver disease. Br Med J (Clin Res Ed) 1985; 291: 25.
36. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al: Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
37. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al: Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1534.
38. Schaaf H, Eipp C, Deubner R, Hesse G, Vasa R, Gieler U: Psychosocial aspects of coping with tinnitus and psoriasis patients. A comparative study of suicidal tendencies, anxiety and depression. HNO 2009; 57: 57-63.
39. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al: National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-1042.
40. Lee FI, Bellary SV, Francis C: Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990; 85: 962-963.
41. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J: Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-155.
42. Qureshi AA, Choi HK, Setty AR, et al: Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009; 145:379-382.
43. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM: Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
44. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al: Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
45. Gisondi P, Targher G, Zoppini G, Girolomoni G:Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-764.
46. Cohen AD, Dreiher J, Birkenfeld S: Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 2009; 23: 561-565.
47. Hanauer SB: Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12(suppl 1):S3-S9.
48. Gisondi P, Del Giglio M, Cozzi A, Girolomoni G:Psoriasis, the liver, and the gastrointestinal tract. Dermatol Ther 2010; 23: 155-159.
49. Gottlieb AB, Chao C, Dann F: Psoriasis comorbidities. J Dermatolog Treat 2008; 19: 5-21.
50. Najarian DJ, Gottlieb AB: Connections between psoriasis and crohn's disease. J Am Acad Dermatol 2003; 48: 805, 21, quiz 822-824.
51. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB: Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
52. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG: Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700-703.
53. Alsufyani MA, Golant AK, Lebwohl M: Psoriasis and the metabolic syndrome. Dermatol Ther 2010; 23:137-143.
54. Lindegard B: Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986; 172: 298-304.
55. de Menezes Ettinger JE, Azaro E, de Souza CA, dos Santos Filho PV, Mello CA, Neves M Jr, et al: Remission of psoriasis after open gastric bypass. Obes Surg 2006; 16: 94-97.
56. Higa-Sansone G, Szomstein S, Soto F, Brasecsco O, Cohen C, Rosenthal RJ: Psoriasis remission after laparoscopic roux-en-Y gastric bypass for morbid obesity. Obes Surg 2004; 14: 1132-1134.
57. Hossler EW, Maroon MS, Mowad CM: Gastric bypass surgery improves psoriasis. J Am Acad Dermatol 2011; 65: 198-200.
58. Mallbris L, Granath F, Hamsten A, Stahle M: Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-621.
59. Liu Z, Fu C, Wang W, Xu B: Prevalence of chronic complications of type 2 diabetes mellitus in outpatients. A cross-sectional hospital based survey in urban China. Health Qual Life Outcomes 2010; 8: 62.
60. Centers for Disease Control and Prevention (CDC):Chronic Disease Prevention and Health Promotion. Success and opportunities for population-based intervention and control. At a Glance 2010. Available from: http://www.cdc.gov/chronicdisease/resources/publications/AAG/ddt.htm. Page last reviewed October 19, 2011. Accessed on October 19, 2011.
61. Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, et al: Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia 2010; 53: 2480-2486.
62. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64(suppl 2):ii14-ii17.
63. Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mork C, et al: Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic psoriasis associations. Data from the Nordic quality of life study. Acta Derm Venereol 2002; 82: 108-113.
64. Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ: Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997; 24: 511-517.
65. Ben-David G, Sheiner E, Hallak M, Levy A: Pregnancy outcome in women with psoriasis. J Reprod Med 2008; 53: 183-187.
66. Lima XT, Janakiraman V, Hughes MD, Kimball AB:The impact of psoriasis on pregnancy outcomes. J Invest Dermatol 2012; 132: 85-91.
67. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life:results of a 1998 national psoriasis foundation patient-membership survey. Arch Dermatol 2001; 137:280-284.
68. Finlay AY, Coles EC: The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-244.
69. Schmitt JM, Ford DE: Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006; 213: 102-110.
70. Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, et al: Cost of moderate to severe plaque psoriasis in Germany. A multicenter cost-of-illness study. Dermatology 2006; 212: 137-144.
71. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ: Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47: 512-518.
72. Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Bradham DD, Exum ML, et al: The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37: 564-569.
73. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M: Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007; 57: 963-971.
74. Andrulis DP: Access to care is the centerpiece in the elimination of socioeconomic disparities in health. Ann Intern Med 1998; 129: 412-416.
75. Henseler T, Christophers E: Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-456.
76. Gupta MA, Gupta AK: Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol 1995; 34: 700-703.
77. Scharloo M, Kaptein AA, Weinman J, Hazes JM, Willems LN, Bergman W, et al: Illness perceptions, coping and functioning in patients with rheumatoid arthritis, chronic obstructive pulmonary disease and psoriasis. J Psychosom Res 1998; 44: 573-585.
78. Scharloo M, Kaptein AA, Weinman JA, Hazes JM, Breedveld FC, Rooijmans HG: Predicting functional status in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1686-1693.
79. Scharloo M, Kaptein AA, Weinman J, Bergman W, Vermeer BJ, Rooijmans HG: Patients' illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. Br J Dermatol 2000; 142: 899-907.
80. Hill L, Kennedy P: The role of coping strategies in mediating subjective disability in people who have psoriasis. Psychol Health Med 2002; 7: 261-269.
81. McCrae R, Costa PT: Personality, coping, and coping effectiveness in an adult sample. J Pers 2006; 54:385-404.
82. Idriss SZ, Kvedar JC, Watson AJ: The role of online support communities: benefits of expanded social networks to patients with psoriasis. Arch Dermatol 2009; 145: 46-51.
83. Picardi A, Mazzotti E, Gaetano P, Cattaruzza MS, Baliva G, Melchi CF, et al: Stress, social support, emotional regulation, and exacerbation of diffuse plaque psoriasis. Psychosomatics 2005; 46: 556-564.
84. Seng TK, Nee TS: Group therapy: a useful and supportive treatment for psoriasis patients. Int J Dermatol 1997; 36: 110-112.
85. Zachariae R, Oster H, Bjerring P, Kragballe K: Effects of psychologic intervention on psoriasis: a preliminary report. J Am Acad Dermatol 1996; 34: 1008-1015.
86. Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CE: A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 2002; 146: 458-465.
87. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
88. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684.
89. Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, et al: Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol 2007; 17: 381-386.
90. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al: A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderateto-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.e1-e15.
91. Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, et al: Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726.